Date: 2015-09-07
Type of information: R&D agreement
Compound: drug delivery devices for oral delivery of peptides
Company: Novo Nordisk (Denmark) Massachusetts Institute of Technology (USA - MA)
Therapeutic area:
Type agreement: R&D
Action mechanism: drug delivery device (DDS)
Disease:
Details: * On September 7, 2015, Novo Nordisk announced that a research collaboration has been initiated with the Langer Laboratory at the Massachusetts Institute of Technology for what is hoped to be the next generation of drug delivery devices for the administration of peptides. The aim of the research collaboration, which is conducted at both MIT in Boston, US and at Novo Nordisk's research facilities in Måløv and Hillerød, Denmark, is to develop the next generation of drug delivery devices as an alternative to parenteral or injection-based delivery of peptides. Professor Robert Langer's laboratory are world-leading experts in creating new approaches for delivering drugs such as peptides and proteins across complex barriers in the body such as the blood-brain barrier, the intestine, the lung and the skin. Together with Dr Giovanni Traverso, a gastroenterologist and biomedical engineer at Harvard Medical School, and research affiliate of MIT, they will lead a team in the development of a platform enabling the oral delivery of peptides.
The collaboration will establish a number of research positions to be hosted by the Langer Laboratory and funded by Novo Nordisk. The initial term of the collaboration is three years with the option to extend for up to three additional years.
Financial terms:
Latest news:
